News from all angles
(MedPage Today) -- A shorter cycle length for a standard treatment for refractory metastatic colorectal cancer was noninferior to the typical longer length for overall survival (OS), while limiting t…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network